Literature DB >> 6195468

Characterization of the cardiotonic effects of milrinone, a new and potent cardiac bipyridine, on isolated tissues from several animal species.

A A Alousi, G P Stankus, J C Stuart, L H Walton.   

Abstract

The cardiotonic activity of milrinone (Win 47203), a potent analogue of amrinone, was demonstrated in isolated guinea pig, cat, rabbit, rat, and hamster atria and papillary muscles. Milrinone, in concentrations of 0.1-300 micrograms/ml, caused concentration-dependent increases in guinea pig papillary muscle and atrial developed tension with minimal increases in atrial rate. Compared with the in vitro inotropic activity of amrinone, milrinone was approximately 30 times more potent. The inotropic and chronotropic effects of milrinone do not appear to be mediated by the release of endogenous norepinephrine, by the direct stimulation of beta-adrenergic or histaminergic receptors, or through the stimulation of prostaglandin synthesis. The inotropic response of the guinea pig papillary muscles to isoproterenol was potentiated when isoproterenol was given at the peak effect of a minimally effective concentration of milrinone or after prolonged incubation with milrinone. No potentiation was observed when isoproterenol was administered at the peak effect of a high concentration of milrinone, which suggests that the positive inotropic action of milrinone may not be solely attributable to cyclic AMP phosphodiesterase inhibition.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6195468     DOI: 10.1097/00005344-198309000-00015

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  21 in total

1.  Involvement of purine compounds in the inotropic action of milrinone.

Authors:  P Dorigo; R M Gaion; I Maragno
Journal:  Cardiovasc Drugs Ther       Date:  1990-04       Impact factor: 3.727

2.  Photolysis of the novel inotropes EMD 57033 and EMD 57439: evidence that Ca2+ sensitization and phosphodiesterase inhibition depend upon the same enantiomeric site.

Authors:  J A Lee; S Palmer; J C Kentish
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

3.  Endothelium-dependent and independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors.

Authors:  N Komas; C Lugnier; J C Stoclet
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

Review 4.  PDE3 Inhibitors Repurposed as Treatments for Age-Related Cognitive Impairment.

Authors:  Shuichi Yanai; Shogo Endo
Journal:  Mol Neurobiol       Date:  2018-10-11       Impact factor: 5.590

Review 5.  Studies on the mechanism of action of the bipyridine milrinone on the heart.

Authors:  A E Farah; C J Frangakis
Journal:  Basic Res Cardiol       Date:  1989       Impact factor: 17.165

6.  Additive positive inotropic effects of milrinone, ouabain and calcium in diseased human ventricular myocardium.

Authors:  L Brown; M Näbauer; E Erdmann
Journal:  Klin Wochenschr       Date:  1986-08-01

7.  Milrinone in heart failure. Effects on exercise haemodynamics during short term treatment.

Authors:  A D Timmis; P Smyth; D E Jewitt
Journal:  Br Heart J       Date:  1985-07

8.  Milrinone in heart failure. Acute effects on left ventricular systolic function and myocardial metabolism.

Authors:  A D Timmis; P Smyth; M Monaghan; L Walker; K Daly; A A McLeod; D E Jewitt
Journal:  Br Heart J       Date:  1985-07

9.  Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside.

Authors:  B E Jaski; M A Fifer; R F Wright; E Braunwald; W S Colucci
Journal:  J Clin Invest       Date:  1985-02       Impact factor: 14.808

10.  Effects of concomitant usage of milrinone and catecholamine for weaning from cardiopulmonary bypass.

Authors:  Y Orime; M Shiono; H Hata; S Yagi; S Tsukamoto; S Kimura; S Ohmiya; A Sezai; H Yamada; M Obana; Y Sezai
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.